Hello,
I am interested in knowing whether there are any ideas or plans to extend target tractability assessments to include alternative modalities, such as single-domain antibodies (VHHs), antisense oligonucleotides (ASOs), multi-specific antibodies, CRISPR-based approaches, etc.
Dear Aki,
thank you so much for posting this question.
At Open Targets, we are currently thinking about expanding our tractability pipelines and are therefore also very keen to get ideas from the Community.
I hope we can start a useful thread!
1 Like